Pharma Deals Review, Vol 2006, No 74 (2006)

Font Size:  Small  Medium  Large

Mayne Pays US$34 M for Rights to SuperGen Oncology

Business Review Editor

Abstract


Mayne Pharma is to acquire the US rights to Nipent®, a chemotherapy agent for the treatment of hairy cell leukemia and SurfaceSafe® from SuperGen for US$34 M including approximately US$14 M upfront.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.